<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03294850</url>
  </required_header>
  <id_info>
    <org_study_id>TRIMDFH 1000376</org_study_id>
    <nct_id>NCT03294850</nct_id>
  </id_info>
  <brief_title>Evaluation of Biomarkers to Quantify Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis at Baseline and Following Bariatric Surgery</brief_title>
  <acronym>BARI</acronym>
  <official_title>Evaluation of Biomarkers to Quantify Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis at Baseline and Following Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate imaging and other biomarkers of non-alcoholic fatty
      liver disease before and after bariatric surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in liver fat post-surgery</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed by magnetic resonance imaging proton density fat fraction (MRI PDFF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline in liver stiffness post-surgery</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed by magnetic resonance elastography (MRE)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>NASH group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These are individuals that have been identified as having NASH by MRE. Confirmation with liver biopsy required for continuation in the longitudinal study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-NASH (NAFLD or normal) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These are individuals that do not have NASH. They either have normal liver physiology or only have evidence of hepatic steatosis. This group will be studied up until the day of their bariatric surgery and will serve as a comparator population with respect to baseline measurements.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric surgery</intervention_name>
    <description>Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied</description>
    <arm_group_label>NASH group</arm_group_label>
    <arm_group_label>Non-NASH (NAFLD or normal) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HepQuant SHUNT Dual Cholate Liver Diagnostic Kit</intervention_name>
    <description>For the experimental group, the device will be used to monitor the effect of bariatric surgery on liver function. For the active comparator group, the device will be used for the assessment of baseline liver function.</description>
    <arm_group_label>NASH group</arm_group_label>
    <arm_group_label>Non-NASH (NAFLD or normal) group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Undergoing bariatric surgery (Roux-en-Y or gastric sleeve only) as part of clinical
             care.

          -  Negative human chorionic gonadotropin (hCG) level (female participants who become
             pregnant during the study will be withdrawn)

          -  For nonalcoholic steatohepatitis (NASH) participants - FibroScan: Controlled
             Attenuation Parameter (CAP) 290 db/m and Vibration-Controlled Transient Elastography
             (VCTE) 8 kilopascal (kPa). For participants who meet FibroScan criteria, inclusion
             will require MRI-PDFF ≥8%; MRE: ≥2.7 kPa.

          -  For NAFLD or normal participants - FibroScan: No requirement for minimum CAP level and
             VCTE &lt;7 kPa. For participants that meet the FibroScan criteria- no requirement for
             minimum MRI-PDFF; MRE ≤ 2 kPa.

          -  Histopathology assessment of liver biopsy that confirms NASH diagnosis

          -  Hemoglobin A1c (HbA1c) ≤ 9.5%

          -  Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

          -  Body mass index (BMI) ≥ 35 kg/m2

          -  Able to speak and understand written and spoken English

          -  Understands the procedures and agrees to participate by giving written informed
             consent

          -  Willing and able to comply with scheduled visits, laboratory tests, and other study
             procedures

        Exclusion Criteria:

          -  Participation in other studies involving investigational drug(s) within 30 days prior
             to Screening Visit 1

          -  History of regular alcohol consumption exceeding 14 drinks/week for females or 21
             drinks/week for males within the previous 6 months

          -  A total score of 8 on the Alcohol Use Disorders Identification Test questionnaire
             (Appendix B), indicating harmful or hazardous ethanol consumption

          -  A positive urine drug test for illicit drugs

          -  Clinical evidence of hepatic decompensation, including, but not limited to esophageal
             varices, ascites, or hepatic encephalopathy

          -  Evidence of other forms of chronic liver disease (including laboratory tests as
             assessed by a sponsor-identified laboratory, and confirmed with a single repeat, if
             needed): Hepatitis B virus (HBV): defined by presence of hepatitis B surface antigen
             (HBsAg); Hepatitis C virus (HCV): As defined by a clinical history of previous
             diagnosis of Hepatitis C (treated or untreated) or a positive Hepatitis C antibody
             (HCVAb); Known diagnosis of primary biliary cirrhosis, primary sclerosing cholangitis,
             autoimmune hepatitis, or overlap syndrome; Alcoholic liver disease; Known diagnosis of
             hemochromatosis; Prior known drug-induced liver injury; Known or suspected
             hepatocellular carcinoma (HCC) or other liver cancer; History of liver transplant,
             current placement on a liver transplant list, or current model of end-stage liver
             disease (MELD) score &gt;12; Histological presence of cirrhosis on a prior biopsy.

          -  Human Immunodeficiency Virus (HIV) infection, defined as presence of HIV antibody

          -  Diagnosis of type 1 diabetes mellitus

          -  Any malignancy not considered cured, except basal cell carcinoma and squamous cell
             carcinoma of the skin (a subject is considered cured if there has been no evidence of
             cancer recurrence in the previous 5 years)

          -  Use of drugs historically associated with non-alcoholic fatty liver disease (NAFLD)
             for 1 month in the previous year prior to Visit 3 (day of Surgery); examples include:
             amiodarone, methotrexate, systemic glucocorticoids, tetracyclines, tamoxifen,
             estrogens at doses greater than those used for hormone replacement, anabolic steroids,
             valproic acid, other known hepatotoxins

          -  Subjects with history of severe claustrophobia impacting ability to perform MRI during
             the study without mild sedation/treatment with an anxiolytic

          -  Subjects who fulfill any of the contraindications for MRI; examples include metal
             implants, devices, paramagnetic objects contained within the body and excessive or
             metal-containing tattoos

          -  Unable to participate in MR assessments due to physical limitations of equipment
             tolerances (MRI bore size and 500-pound weight limit) based on Investigator's judgment
             at screening

          -  Any person unable to lie still within the environment of the MRI scanner or maintain a
             breath hold for the required period to acquire images without mild sedation/treatment
             with an anxiolytic

          -  Subjects with any anatomical or pathological abnormality that would either preclude or
             tend to confound the analysis of study data, including any clinically significant
             abnormal findings on the MRI obtained at Screening Visit 2.

          -  Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more
             within 56 days prior to Screening Visit 1 (participants may not donate blood any time
             during the study, through the final study visit)

          -  Known history or suspected hypersensitivity to human serum albumin, or its
             preparations.

          -  Investigator site staff members directly involved in the conduct of the study and
             their family members, site staff members otherwise supervised by the investigator, or
             subjects who are Pfizer employees, including their family members, directly involved
             in the conduct of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quianna Stokes-Washington</last_name>
    <phone>407-303-7100</phone>
    <email>tri@flhosp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Quianna Stokes-Washington</last_name>
      <phone>407-303-7100</phone>
      <email>tri@flhosp.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tri-md.org</url>
    <description>Translational Research Institute for Metabolism and Diabetes</description>
  </link>
  <reference>
    <citation>Ahmed MH, Abu EO, Byrne CD. Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Prim Care Diabetes. 2010 Oct;4(3):129-37. doi: 10.1016/j.pcd.2010.02.004. Epub 2010 Mar 17. Review.</citation>
    <PMID>20299294</PMID>
  </reference>
  <reference>
    <citation>Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686-90. doi: 10.1038/nrgastro.2013.171. Epub 2013 Sep 17. Review.</citation>
    <PMID>24042449</PMID>
  </reference>
  <reference>
    <citation>Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x. Epub 2011 May 30. Review.</citation>
    <PMID>21623852</PMID>
  </reference>
  <reference>
    <citation>Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L; American Association for the Study of Liver Diseases; United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015 Apr;61(4):1392-405. doi: 10.1002/hep.27678. Epub 2015 Mar 19.</citation>
    <PMID>25557690</PMID>
  </reference>
  <reference>
    <citation>Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011 Jun 24;332(6037):1519-23. doi: 10.1126/science.1204265. Review.</citation>
    <PMID>21700865</PMID>
  </reference>
  <reference>
    <citation>Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T; LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005 Jun;128(7):1898-906.</citation>
    <PMID>15940625</PMID>
  </reference>
  <reference>
    <citation>Alkhouri N, McCullough AJ. Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012 Oct;8(10):661-8.</citation>
    <PMID>24683373</PMID>
  </reference>
  <reference>
    <citation>Papagianni M, Sofogianni A, Tziomalos K. Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol. 2015 Apr 8;7(4):638-48. doi: 10.4254/wjh.v7.i4.638. Review.</citation>
    <PMID>25866601</PMID>
  </reference>
  <reference>
    <citation>Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol. 2016 Nov;65(5):1006-1016. doi: 10.1016/j.jhep.2016.06.005. Epub 2016 Jun 14. Review.</citation>
    <PMID>27312947</PMID>
  </reference>
  <reference>
    <citation>Hashemi SA, Alavian SM, Gholami-Fesharaki M. Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Caspian J Intern Med. 2016 Fall;7(4):242-252.</citation>
    <PMID>27999641</PMID>
  </reference>
  <reference>
    <citation>Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol. 2006 Feb;101(2):368-73.</citation>
    <PMID>16454845</PMID>
  </reference>
  <reference>
    <citation>Rabl C, Campos GM. The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis. 2012 Feb;32(1):80-91. doi: 10.1055/s-0032-1306428. Epub 2012 Mar 13. Review.</citation>
    <PMID>22418890</PMID>
  </reference>
  <reference>
    <citation>Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? J Obes. 2013;2013:839275. doi: 10.1155/2013/839275. Epub 2013 Jan 29. Review.</citation>
    <PMID>23431426</PMID>
  </reference>
  <reference>
    <citation>Schneck AS, Anty R, Patouraux S, Bonnafous S, Rousseau D, Lebeaupin C, Bailly-Maitre B, Sans A, Tran A, Gugenheim J, Iannelli A, Gual P. Roux-En Y Gastric Bypass Results in Long-Term Remission of Hepatocyte Apoptosis and Hepatic Histological Features of Non-alcoholic Steatohepatitis. Front Physiol. 2016 Aug 19;7:344. doi: 10.3389/fphys.2016.00344. eCollection 2016.</citation>
    <PMID>27594839</PMID>
  </reference>
  <reference>
    <citation>Alizai PH, Wendl J, Roeth AA, Klink CD, Luedde T, Steinhoff I, Neumann UP, Schmeding M, Ulmer F. Functional Liver Recovery After Bariatric Surgery--a Prospective Cohort Study with the LiMAx Test. Obes Surg. 2015 Nov;25(11):2047-53. doi: 10.1007/s11695-015-1664-0.</citation>
    <PMID>25869925</PMID>
  </reference>
  <reference>
    <citation>Barr J, Caballería J, Martínez-Arranz I, Domínguez-Díez A, Alonso C, Muntané J, Pérez-Cormenzana M, García-Monzón C, Mayo R, Martín-Duce A, Romero-Gómez M, Lo Iacono O, Tordjman J, Andrade RJ, Pérez-Carreras M, Le Marchand-Brustel Y, Tran A, Fernández-Escalante C, Arévalo E, García-Unzueta M, Clement K, Crespo J, Gual P, Gómez-Fleitas M, Martínez-Chantar ML, Castro A, Lu SC, Vázquez-Chantada M, Mato JM. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res. 2012 Apr 6;11(4):2521-32. doi: 10.1021/pr201223p. Epub 2012 Mar 15.</citation>
    <PMID>22364559</PMID>
  </reference>
  <reference>
    <citation>Nielsen MJ, Nedergaard AF, Sun S, Veidal SS, Larsen L, Zheng Q, Suetta C, Henriksen K, Christiansen C, Karsdal MA, Leeming DJ. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res. 2013 Apr 19;5(3):303-15. Print 2013.</citation>
    <PMID>23634241</PMID>
  </reference>
  <reference>
    <citation>Nielsen MJ, Veidal SS, Karsdal MA, Ørsnes-Leeming DJ, Vainer B, Gardner SD, Hamatake R, Goodman ZD, Schuppan D, Patel K. Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int. 2015 Feb;35(2):429-37. doi: 10.1111/liv.12700. Epub 2014 Oct 29.</citation>
    <PMID>25308921</PMID>
  </reference>
  <reference>
    <citation>Helmke S, Colmenero J, Everson GT. Noninvasive assessment of liver function. Curr Opin Gastroenterol. 2015 May;31(3):199-208. doi: 10.1097/MOG.0000000000000167. Review.</citation>
    <PMID>25714706</PMID>
  </reference>
  <reference>
    <citation>Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014 May;146(6):1513-24. doi: 10.1053/j.gastro.2014.01.020. Epub 2014 Jan 15. Review.</citation>
    <PMID>24440671</PMID>
  </reference>
  <reference>
    <citation>Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep. 2014 Feb;16(2):372. doi: 10.1007/s11894-014-0372-6. Review.</citation>
    <PMID>24452634</PMID>
  </reference>
  <reference>
    <citation>Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 2011 Jun;259(3):749-56. doi: 10.1148/radiol.11101942. Epub 2011 Apr 1.</citation>
    <PMID>21460032</PMID>
  </reference>
  <reference>
    <citation>Thomas MS, Newman D, Leinhard OD, Kasmai B, Greenwood R, Malcolm PN, Karlsson A, Rosander J, Borga M, Toms AP. Test-retest reliability of automated whole body and compartmental muscle volume measurements on a wide bore 3T MR system. Eur Radiol. 2014 Sep;24(9):2279-91. doi: 10.1007/s00330-014-3226-6. Epub 2014 May 29.</citation>
    <PMID>24871333</PMID>
  </reference>
  <reference>
    <citation>Karlsson A, Rosander J, Romu T, Tallberg J, Grönqvist A, Borga M, Dahlqvist Leinhard O. Automatic and quantitative assessment of regional muscle volume by multi-atlas segmentation using whole-body water-fat MRI. J Magn Reson Imaging. 2015 Jun;41(6):1558-69. doi: 10.1002/jmri.24726. Epub 2014 Aug 11.</citation>
    <PMID>25111561</PMID>
  </reference>
  <reference>
    <citation>West J, Dahlqvist Leinhard O, Romu T, Collins R, Garratt S, Bell JD, Borga M, Thomas L. Feasibility of MR-Based Body Composition Analysis in Large Scale Population Studies. PLoS One. 2016 Sep 23;11(9):e0163332. doi: 10.1371/journal.pone.0163332. eCollection 2016.</citation>
    <PMID>27662190</PMID>
  </reference>
  <reference>
    <citation>Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R, Collier JD, Booth JC, Schneider JE, Wang LM, Delaney DW, Fleming KA, Robson MD, Barnes E, Neubauer S. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 2014 Jan;60(1):69-77. doi: 10.1016/j.jhep.2013.09.002. Epub 2013 Sep 12.</citation>
    <PMID>24036007</PMID>
  </reference>
  <reference>
    <citation>Pavlides M, Banerjee R, Sellwood J, Kelly CJ, Robson MD, Booth JC, Collier J, Neubauer S, Barnes E. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 2016 Feb;64(2):308-315. doi: 10.1016/j.jhep.2015.10.009. Epub 2015 Nov 10.</citation>
    <PMID>26471505</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

